Portal de Periódicos da CAPES

Gleason 6 Prostate Cancer: Translating Biology into Population Health

2015; Lippincott Williams & Wilkins; Volume: 194; Issue: 3 Linguagem: Inglês

10.1016/j.juro.2015.01.126

1527-3792

Scott E. Eggener, Ketan K. Badani, Daniel A. Barocas, Glen W. Barrisford, Jed-Sian Cheng, Arnold I. Chin, Anthony Corcoran, Jonathan I. Epstein, Arvin K. George, Gopal N. Gupta, Matthew H. Hayn, Eric Kauffman, Brian R. Lane, Michael A. Liss, Moben Mirza, Todd M. Morgan, Kelvin A. Moses, Kenneth G. Nepple, Mark Preston, Soroush Rais‐Bahrami, Matthew J. Resnick, M. Minhaj Siddiqui, Jonathan L. Silberstein, Eric A. Singer, Geoffrey A. Sonn, Preston Sprenkle, Kelly Stratton, Jennifer Taylor, Jeffrey Tomaszewski, Matt Tollefson, Andrew J. Vickers, Wesley M. White, William T. Lowrance,

Genital Health and Disease

Gleason 6 (3+3) is the most commonly diagnosed prostate cancer among men with prostate specific antigen screening, the most histologically well differentiated and is associated with the most favorable prognosis. Despite its prevalence, considerable debate exists regarding the genetic features, clinical significance, natural history, metastatic potential and optimal management.